Literature DB >> 35430689

Spinal cord sarcoidosis in Japan: utility of cerebrospinal fluid examination and nerve conduction study for diagnosis and prognosis prediction.

Miwako Fujisawa1, Michiaki Koga1, Ryota Sato1, Mariko Oishi1, Yukio Takeshita1, Takashi Kanda2.   

Abstract

Spinal cord sarcoidosis (SCS) is rare, and its diagnosis is challenging. We examined clinical, laboratory, and imaging features in patients with SCS to obtain useful clues for diagnosis and prognosis. Eleven consecutive patients (four males, seven females) at a single Japanese institution were investigated. Median age at onset was 66 years old. The most frequent site affected, other than the nervous system, was the respiratory system. While histological confirmation of non-caseating granulomas was often found there, no patient had respiratory symptoms. Peripheral nerve involvement was detected in 64% of patients. Soluble IL-2 receptor (sIL-2R) levels in serum and cerebrospinal fluid (CSF) were elevated in 64% and 45% of patients, respectively, and this finding was more common than elevation of angiotensin-converting enzyme (ACE). 18F-fluorodeoxyglucose (FDG) positron emission tomography showed abnormally high uptake in spinal lesions of all examined patients. Although corticosteroids were administrated to all patients, and immuno-suppressants were prescribed to six (55%), the modified Rankin Scale was unchanged or worsened in four (36%) patients during the follow-up period. Neurological exacerbation of myelopathy was seen in four (36%) patients. Complete response rate was only seen in 9%. High levels of cell count, protein, ACE, and sIL-2R in CSF were significantly more frequent in patients with a marked improvement after immunotherapy than in the other patients. These results suggest that high serum and CSF sIL-2R, high uptake of FDG, and peripheral nerve involvement are indicative of SCS. Given that SCS is commonly intractable, CSF abnormalities may predict efficacy of immunotherapies.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Nerve conduction study; PET; Sarcoidosis; Spinal cord; sIL-2R

Mesh:

Substances:

Year:  2022        PMID: 35430689     DOI: 10.1007/s00415-022-11113-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   6.682


  34 in total

Review 1.  Epidemiology and clinical characteristics of sarcoidosis: an update from a population-based cohort study from Olmsted County, Minnesota.

Authors:  P Ungprasert; C S Crowson; E L Matteson
Journal:  Reumatismo       Date:  2017-05-22

Review 2.  Geoepidemiological big data approach to sarcoidosis: geographical and ethnic determinants.

Authors:  Pilar Brito-Zerón; Belchin Kostov; Daphne Superville; Robert P Baughman; Manuel Ramos-Casals
Journal:  Clin Exp Rheumatol       Date:  2019-08-26       Impact factor: 4.473

3.  Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan.

Authors:  Michiru Sawahata; Yukihiko Sugiyama; Yosikazu Nakamura; Masayuki Nakayama; Naoko Mato; Hideaki Yamasawa; Masashi Bando
Journal:  Respir Med       Date:  2015-01-03       Impact factor: 3.415

Review 4.  Sarcoidosis.

Authors:  Dominique Valeyre; Antje Prasse; Hilario Nunes; Yurdagul Uzunhan; Pierre-Yves Brillet; Joachim Müller-Quernheim
Journal:  Lancet       Date:  2013-10-01       Impact factor: 79.321

5.  Epidemiology of sarcoidosis in Japan.

Authors:  T Morimoto; A Azuma; S Abe; J Usuki; S Kudoh; K Sugisaki; M Oritsu; T Nukiwa
Journal:  Eur Respir J       Date:  2007-10-24       Impact factor: 16.671

6.  Sarcoidosis in America. Analysis Based on Health Care Use.

Authors:  Robert P Baughman; Shelli Field; Ulrich Costabel; Ronald G Crystal; Daniel A Culver; Marjolein Drent; Marc A Judson; Gerhard Wolff
Journal:  Ann Am Thorac Soc       Date:  2016-08

Review 7.  Neurosarcoidosis: a clinical dilemma.

Authors:  Elske Hoitsma; Carin G Faber; Marjolein Drent; Om P Sharma
Journal:  Lancet Neurol       Date:  2004-07       Impact factor: 44.182

8.  Characteristics of 68 patients with clinically proven sarcoidosis based on the Japan Society of Sarcoidosis and Other Granulomatous Disorders 2015 criteria.

Authors:  Yoshitaka Yamanouchi; Michiru Sawahata; Noritaka Sakamoto; Shu Hisata; Noriharu Shijubo; Satoshi Konno; Tetsuo Yamaguchi; Meri Watanabe; Hidetoshi Kawashima; Takuji Suzuki; Masashi Bando; Koichi Hagiwara
Journal:  Respir Investig       Date:  2019-12-26

9.  Subacute myelopathy as the presenting manifestation of sarcoidosis.

Authors:  J Bogousslavsky; J P Hungerbühler; F Regli; H J Graf
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

10.  Central nervous system sarcoidosis--diagnosis and management.

Authors:  J P Zajicek; N J Scolding; O Foster; M Rovaris; J Evanson; I F Moseley; J W Scadding; E J Thompson; V Chamoun; D H Miller; W I McDonald; D Mitchell
Journal:  QJM       Date:  1999-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.